Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov 25:15:72.
doi: 10.1186/s13223-019-0376-8. eCollection 2019.

The International/Canadian Hereditary Angioedema Guideline

Affiliations
Review

The International/Canadian Hereditary Angioedema Guideline

Stephen Betschel et al. Allergy Asthma Clin Immunol. .

Erratum in

  • Correction to: The International/Canadian Hereditary Angioedema Guideline.
    Betschel S, Badiou J, Binkley K, Borici-Mazi R, Hébert J, Kanani A, Keith P, Lacuesta G, Waserman S, Yang B, Aygören-Pürsün E, Bernstein J, Bork K, Caballero T, Cicardi M, Craig T, Farkas H, Grumach A, Katelaris C, Longhurst H, Riedl M, Zuraw B, Berger M, Boursiquot JN, Boysen H, Castaldo A, Chapdelaine H, Connors L, Fu L, Goodyear D, Haynes A, Kamra P, Kim H, Lang-Robertson K, Leith E, McCusker C, Moote B, O'Keefe A, Othman I, Poon MC, Ritchie B, St-Pierre C, Stark D, Tsai E. Betschel S, et al. Allergy Asthma Clin Immunol. 2020 May 6;16:33. doi: 10.1186/s13223-020-00430-4. eCollection 2020. Allergy Asthma Clin Immunol. 2020. PMID: 32399057 Free PMC article.

Abstract

This is an update to the 2014 Canadian Hereditary Angioedema Guideline with an expanded scope to include the management of hereditary angioedema (HAE) patients worldwide. It is a collaboration of Canadian and international HAE experts and patient groups led by the Canadian Hereditary Angioedema Network. The objective of this guideline is to provide evidence-based recommendations, using the GRADE system, for the management of patients with HAE. This includes the treatment of attacks, short-term prophylaxis, long-term prophylaxis, and recommendations for self-administration, individualized therapy, quality of life, and comprehensive care. New to the 2019 version of this guideline are sections covering the diagnosis and recommended therapies for acute treatment in HAE patients with normal C1-INH, as well as sections on pregnant and paediatric patients, patient associations and an HAE registry. Hereditary angioedema results in random and often unpredictable attacks of painful swelling typically affecting the extremities, bowel mucosa, genitals, face and upper airway. Attacks are associated with significant functional impairment, decreased health-related quality of life, and mortality in the case of laryngeal attacks. Caring for patients with HAE can be challenging due to the complexity of this disease. The care of patients with HAE in Canada, as in many countries, continues to be neither optimal nor uniform. It lags behind some other countries where there are more organized models for HAE management, and greater availability of additional licensed therapeutic options. It is anticipated that providing this guideline to caregivers, policy makers, patients, and advocates will not only optimize the management of HAE, but also promote the importance of individualized care. The primary target users of this guideline are healthcare providers who are managing patients with HAE. Other healthcare providers who may use this guideline are emergency and intensive care physicians, primary care physicians, gastroenterologists, dentists, otolaryngologists, paediatricians, and gynaecologists who will encounter patients with HAE and need to be aware of this condition. Hospital administrators, insurers and policy makers may also find this guideline helpful.

Keywords: Acute attacks; Guideline; Hereditary angioedema; Long-term prophylaxis; Patient registry; Pediatrics; Pregnancy; Quality of life; Recommendations; Short-term prophylaxis.

PubMed Disclaimer

Conflict of interest statement

Competing interestsDetails of potential conflicts of interest (COI) were elicited using the standardized “International Committee of Medical Journal Editors Form for Disclosure of Potential Conflicts of Interest”. COI forms were distributed to attendees prior to their review of the manuscript, and were mandatory for all contributing authors.

References

    1. Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol. 2012;130(3):692–697. doi: 10.1016/j.jaci.2012.05.055. - DOI - PubMed
    1. Agostoni A, Aygören-Pürsün E, Binkley KE, Blanch A, Bork K, Bouillet L, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114(3):S51–S131. doi: 10.1016/j.jaci.2004.06.047. - DOI - PMC - PubMed
    1. Zilberberg MD, Jacobsen T, Tillotson G. The burden of hospitalizations and emergency department visits with hereditary angioedema and angioedema in the United States, 2007. 2010. http://www.ingentaconnect.com/content/ocean/aap/2010/00000031/00000006/a.... Accessed 20 Mar 2019. - PubMed
    1. Cicardi M, Agostoni A. Hereditary Angioedema. N Engl J Med. 1996;334(25):1666–1667. doi: 10.1056/NEJM199606203342510. - DOI - PubMed
    1. Zuraw BL. Hereditary angioedema. N Engl J Med. 2008;359(10):1027–1036. doi: 10.1056/NEJMcp0803977. - DOI - PubMed

LinkOut - more resources